New treatment for non-segmental vitiligo on the face and body
Part of Skin clinical trials.
This study tests a new medication called FXS5626 to help treat non-segmental vitiligo (a type of vitiligo that affects both sides of the body). It is for people who have moderate to large patches of vitiligo, especially on the face.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 12 and 75 years old (for the phase 3 part of the study)
- Have a body mass index (BMI) of at least 18
- Have vitiligo that covers at least 3% of your body, not counting the palms, soles, and tops of hands/feet
- Have at least some vitiligo on your face (at least 0.5% of your body surface)
- Be willing to use reliable birth control (like condoms or an IUD) during the study and not donate sperm or eggs
- Not have more than 33% of the affected skin with white hairs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental medication (ACT-777991) taken by mouth to see if it can help repigment skin in adults with non-segmental vitiligo. It aims to learn how safe it is and how well it works.
This study tests a new drug called EI-001 for people with non-segmental vitiligo (a type where white patches appear on both sides of the body). It is for those whose vitiligo has not gotten better with standard treatments like creams or light therapy, or who cannot use those treatments.
This study tests an investigational drug (GIA632) in people with non-segmental vitiligo. It aims to see if different doses can safely and effectively restore color to white patches.
This trial tests an oral tablet called VC005 to see if it can help treat non-segmental vitiligo. It may be an option for adults with vitiligo patches that are not limited to one area of the body.
This trial tests two forms of a drug (SHR0302) for non-segmental vitiligo. One is a pill, the other a gel. The goal is to see if they can repigment the skin with fewer side effects.
This trial tests an investigational drug called ICP-332 for vitiligo that isn't limited to one area (non-segmental). It aims to see if the drug can help restore skin color. The study is for both adults and teenagers who have had vitiligo for at least 3 months with a certain amount of skin affected.
Hear when a new Non-segmental Vitiligo trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.